ライフサイエンスコーパス: symptomatic treatment

1 ly to be underdiagnosed and can benefit from symptomatic treatment.

2 nd quality of life and time to initiation of symptomatic treatment.

3 Currently, there is no cure for asthma, only symptomatic treatment.

4 Corticosteroids could be an alternative symptomatic treatment.

5 ound studies in both neurorehabilitation and symptomatic treatment.

6 t the value of therapeutic interventions for symptomatic treatment.

7 erating cysticercus and will also respond to symptomatic treatment.

8 t person at the right time, rather than just symptomatic treatment.

9 other maintenance immunotherapies as well as symptomatic treatments.

10 vational data gathered on symptomatology and symptomatic treatments.

11 ic patients who were unresponsive to optimal symptomatic treatments.

12 TSC-related research and challenged existing symptomatic treatments.

13 eath will be developed to complement current symptomatic treatments.

14 bo (n = 81); 92% concurrently used 1 or more symptomatic treatments (94% for amoxicillin group vs 90%

15 Our data suggest symptomatic treatment alone for immunocompetent patients

16 ; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration le

17 Symptomatic treatment and reassurance is the preferred i

18 is, the relatively few evaluative studies in symptomatic treatment and rehabilitation have meant that

19 Symptomatic treatment and the currently available therap

20 her therapeutic agents, appear warranted, as symptomatic treatments and neuroprotective treatments ar

21 (nine patients) response to immunotherapy or symptomatic treatment, and three died.

22 Many other symptomatic treatments appear helpful to individuals in

23 immunodeficiency virus (HIV) but few data on symptomatic treatment are available.

24 Although the main symptomatic treatments are intranasal corticosteroids (I

25 The options for symptomatic treatments are limited, but a potential targ

26 Symptomatic treatments are modestly effective and offer

27 Symptomatic treatments are quite effective in early dise

28 This and other trials of symptomatic treatments are reviewed.

29 Cox proportional hazards model using time to symptomatic treatment as the dependent variable.

30 clude oral therapies, monoclonal antibodies, symptomatic treatments as well as insights into neuropro

31 Effective symptomatic treatment can be achieved with medication an

32 In rare cases for which symptomatic treatment does not control dyspnoea to the p

33 ificantly alter the disease course, but many symptomatic treatments exist to improve patients' qualit

34 Surgery should be reserved for severely symptomatic treatment failures.

35 The current frontline symptomatic treatment for Alzheimer's disease (AD) is wh

36 rgeting IL-1beta signaling may offer a novel symptomatic treatment for CJD.SIGNIFICANCE STATEMENT Dem

37 Resynchronization pacing is an effective symptomatic treatment for heart failure patients with pr

38 ep brain stimulation therapy is an effective symptomatic treatment for Parkinson's disease, yet the p

39 Currently, only symptomatic treatment for PD is available.

40 ate diagnosis is important because effective symptomatic treatment for PD is available.

41 and emphasize the importance of appropriate symptomatic treatment for these individuals.

42 ll patients received a 5- to 7-day supply of symptomatic treatments for pain, fever, cough, and nasal

43 dopa and the dopamine agonists are effective symptomatic treatments for Parkinson's disease, and all

44 dentified genes, and innovative experimental symptomatic treatments for these devastating disorders.

45 ate model of PD that could be useful to test symptomatic treatments for these heavily disabling sympt

46 eting pharmacological or non-pharmacological symptomatic treatment in ALS are examples of areas that

47 E inhibitors, which are potentially superior symptomatic treatments in late-stage Alzheimer's disease

48 Symptomatic treatment includes cholestyramine and antidi

49 Symptomatic treatment includes supplementing fiber to ac

50 Palliative and symptomatic treatment is based on surgical debulking, tu

51 The mainstay of symptomatic treatment is levodopa.

52 median 3-year follow-up of 132 patients with symptomatic treatment-naive and relapsed/refractory CLL

53 mmunotherapy tablet in addition to effective symptomatic treatment of allergic rhinoconjunctivitis.

54 tylcholinesterase inhibitors (AChEIs) during symptomatic treatment of Alzheimer's disease, we report

55 (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer's disease, with possi

56 acetylcholinesterase inhibitors approved for symptomatic treatment of Alzheimer's disease.

57 Methylphenidate (MPH) is an effective symptomatic treatment of attention deficit hyperactivity

58 cal disorders and indicate the potential for symptomatic treatment of behavioural variant frontotempo

59 the approval of this class of agents for the symptomatic treatment of CHF, but long-term studies are

60 The average optimal contact used in symptomatic treatment of early PD patients was: anterior

61 el and functionally selective target for the symptomatic treatment of excessive weight gain associate

62 t 3,4-diaminopyridine may play a role in the symptomatic treatment of fatigue in multiple sclerosis.

63 anticholinergic agent, may be useful in the symptomatic treatment of functional bowel disorders.

64 nhibitor tetrabenazine, presently in use for symptomatic treatment of hyperkinetic disorders.

65 Compounds of this type may be useful in the symptomatic treatment of memory impairment associated wi

66 herapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study

67 e, an oral prokinetic drug indicated for the symptomatic treatment of nocturnal heartburn due to gast

68 cyclooxygenase-2 inhibitor developed for the symptomatic treatment of osteoarthritis and acute pain.

69 effective pharmacological agent used for the symptomatic treatment of Parkinson's disease but long-te

70 Although progress has been made in the symptomatic treatment of Parkinson's disease since the d

71 L-DOPA has been the gold standard for symptomatic treatment of Parkinson's disease.

72 nting, steady advances are being made in the symptomatic treatment of Parkinson's disease.

73 ceptor subtypes as potential targets for the symptomatic treatment of parkinsonian-like motor symptom

74 ventral pallidotomy has been employed in the symptomatic treatment of patients with advanced Parkinso

75 n proposed recently as an alternative in the symptomatic treatment of patients with hypertrophic obst

76 reotide has some efficacy and is safe in the symptomatic treatment of patients with inoperable bowel

77 cated as a useful adjunct to levodopa in the symptomatic treatment of patients with PD with and witho

78 een suggested as an alternative approach for symptomatic treatment of PD.

79 Symptomatic treatment of SOD1(G93A) mice from 70 days of

80 dies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in chroni

81 ically available drugs may be beneficial for symptomatic treatment of the disease.

82 the data have potential implications for the symptomatic treatment of the disease.

83 vention is likely to remain important in the symptomatic treatment of this disabling disease.

84 for LEMS, and the current most commonly used symptomatic treatment option is a potassium channel bloc

85 and anticholinergic medications are used for symptomatic treatment, significant deficits in cholinerg

86 nt is still elusive, the currently available symptomatic treatment strategies are quite effective for

87 dementia, which helps to guide clinicians in symptomatic treatment strategies.

88 ate key aspects of disease pathology and its symptomatic treatment suggests that this neuromuscular j

89 of therapeutic strategies--from conservative symptomatic treatment to curative hematopoietic stem cel

90 areness that health care must move from post-symptomatic treatment to presymptomatic intervention.

91 (CF), shifts the paradigm from conventional symptomatic treatments to therapeutics directly tackling

92 tomatic Prevention trial patients, and 2,567 symptomatic Treatment trial patients.

93 e same time, we evaluated the indications of symptomatic treatment using ASCA score.

94 Symptomatic treatment using cholinergic drugs may thus b

95 Management strategies include symptomatic treatment with corticosteroids and anticonvu

96 uced diarrhea (CID) has customarily involved symptomatic treatment with opioids in conjunction with s